Cargando…
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals
OBJECTIVE. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown etiology. Epstein-Barr virus (EBV) is an environmental factor associated with SLE. EBV maintains latency in B cells with frequent reactivation measured by antibodies against viral capsid antigen (VCA) and ear...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692217/ https://www.ncbi.nlm.nih.gov/pubmed/31217170 http://dx.doi.org/10.1136/annrheumdis-2019-215361 |
_version_ | 1783443512370397184 |
---|---|
author | Jog, Neelakshi R. Young, Kendra A. Munroe, Melissa E. Harmon, Michael T. Guthridge, Joel M. Kelly, Jennifer A. Kamen, Diane L. Gilkeson, Gary S. Weisman, Michael H. Karp, David R. Gaffney, Patrick M. Harley, John B. Wallace, Daniel J. Norris, Jill M. James, Judith A. |
author_facet | Jog, Neelakshi R. Young, Kendra A. Munroe, Melissa E. Harmon, Michael T. Guthridge, Joel M. Kelly, Jennifer A. Kamen, Diane L. Gilkeson, Gary S. Weisman, Michael H. Karp, David R. Gaffney, Patrick M. Harley, John B. Wallace, Daniel J. Norris, Jill M. James, Judith A. |
author_sort | Jog, Neelakshi R. |
collection | PubMed |
description | OBJECTIVE. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown etiology. Epstein-Barr virus (EBV) is an environmental factor associated with SLE. EBV maintains latency in B cells with frequent reactivation measured by antibodies against viral capsid antigen (VCA) and early antigen (EA). In this study, we determined whether EBV reactivation and single nucleotide polymorphisms (SNPs) in EBV-associated host genes are associated with SLE transition. METHODS. SLE patient relatives (n=436) who did not have SLE at baseline were re-contacted after 6.3 (±3.9) years and evaluated for interim transitioning to SLE (≥4 cumulative ACR criteria); 56 (13%) transitioned to SLE prior to the follow-up visit. At both visits, detailed demographic, environmental, clinical information, and blood samples were obtained. Antibodies against viral antigens were measured by ELISA. SNPs in IL10, CR2, TNFAIP3, and CD40 genes were typed by ImmunoChip™. Generalized estimating equations were used to test associations between viral antibody levels and transitioning to SLE. RESULTS. Mean baseline VCA IgG (4.879±1.797 vs 3.866±1.795, p=0.0003) and EA IgG (1.192±1.113 vs 0.7774±0.8484, p=0.0236) levels were higher in transitioned compared to autoantibody negative non-transition relatives. Increased VCA IgG and EA IgG were associated with transitioning to SLE (OR 1.28 95%CI 1.07–1.53 p=0.007, OR 1.43 95%CI 1.06–1.93 p=0.02, respectively). Significant interactions were observed between CD40 variant rs48100485 and VCA IgG levels, and IL10 variant rs3024493 and VCA IgA levels in transitioning to SLE. CONCLUSION. Heightened serologic reactivation of EBV increases the probability of transitioning to SLE in unaffected SLE relatives. |
format | Online Article Text |
id | pubmed-6692217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-66922172019-09-01 Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals Jog, Neelakshi R. Young, Kendra A. Munroe, Melissa E. Harmon, Michael T. Guthridge, Joel M. Kelly, Jennifer A. Kamen, Diane L. Gilkeson, Gary S. Weisman, Michael H. Karp, David R. Gaffney, Patrick M. Harley, John B. Wallace, Daniel J. Norris, Jill M. James, Judith A. Ann Rheum Dis Article OBJECTIVE. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with unknown etiology. Epstein-Barr virus (EBV) is an environmental factor associated with SLE. EBV maintains latency in B cells with frequent reactivation measured by antibodies against viral capsid antigen (VCA) and early antigen (EA). In this study, we determined whether EBV reactivation and single nucleotide polymorphisms (SNPs) in EBV-associated host genes are associated with SLE transition. METHODS. SLE patient relatives (n=436) who did not have SLE at baseline were re-contacted after 6.3 (±3.9) years and evaluated for interim transitioning to SLE (≥4 cumulative ACR criteria); 56 (13%) transitioned to SLE prior to the follow-up visit. At both visits, detailed demographic, environmental, clinical information, and blood samples were obtained. Antibodies against viral antigens were measured by ELISA. SNPs in IL10, CR2, TNFAIP3, and CD40 genes were typed by ImmunoChip™. Generalized estimating equations were used to test associations between viral antibody levels and transitioning to SLE. RESULTS. Mean baseline VCA IgG (4.879±1.797 vs 3.866±1.795, p=0.0003) and EA IgG (1.192±1.113 vs 0.7774±0.8484, p=0.0236) levels were higher in transitioned compared to autoantibody negative non-transition relatives. Increased VCA IgG and EA IgG were associated with transitioning to SLE (OR 1.28 95%CI 1.07–1.53 p=0.007, OR 1.43 95%CI 1.06–1.93 p=0.02, respectively). Significant interactions were observed between CD40 variant rs48100485 and VCA IgG levels, and IL10 variant rs3024493 and VCA IgA levels in transitioning to SLE. CONCLUSION. Heightened serologic reactivation of EBV increases the probability of transitioning to SLE in unaffected SLE relatives. 2019-06-19 2019-09 /pmc/articles/PMC6692217/ /pubmed/31217170 http://dx.doi.org/10.1136/annrheumdis-2019-215361 Text en http://creativecommons.org/licenses/by/4.0/ License Statement. I, the Submitting Author, have the right to grant and do grant on behalf of all authors of the Work (as defined in the below author license), an exclusive license and/or a non-exclusive license for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY license shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and, where the relevant Journal is co-owned by BMJ, to the co-owners of the Journal, to publish the Work in Annals of the Rheumatic Diseases and any other BMJ products and to exploit all rights, as set out in our license (https://authors.bmj.com/wp-content/uploads/2018/11/BMJ_Journals_Combined_Author_Licence_2018.pdf) .The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons license – details of these licenses and which Creative Commons (http://creativecommons.org/) license will apply to this Work are set out in our license referred to above. |
spellingShingle | Article Jog, Neelakshi R. Young, Kendra A. Munroe, Melissa E. Harmon, Michael T. Guthridge, Joel M. Kelly, Jennifer A. Kamen, Diane L. Gilkeson, Gary S. Weisman, Michael H. Karp, David R. Gaffney, Patrick M. Harley, John B. Wallace, Daniel J. Norris, Jill M. James, Judith A. Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
title | Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
title_full | Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
title_fullStr | Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
title_full_unstemmed | Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
title_short | Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
title_sort | association of epstein-barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692217/ https://www.ncbi.nlm.nih.gov/pubmed/31217170 http://dx.doi.org/10.1136/annrheumdis-2019-215361 |
work_keys_str_mv | AT jogneelakshir associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT youngkendraa associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT munroemelissae associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT harmonmichaelt associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT guthridgejoelm associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT kellyjennifera associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT kamendianel associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT gilkesongarys associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT weismanmichaelh associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT karpdavidr associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT gaffneypatrickm associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT harleyjohnb associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT wallacedanielj associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT norrisjillm associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals AT jamesjuditha associationofepsteinbarrvirusserologicalreactivationwithtransitioningtosystemiclupuserythematosusinatriskindividuals |